Advertisement

Drugs

, Volume 62, Issue 9, pp 1345–1353 | Cite as

Olmesartan Medoxomil

  • Gregory T. WarnerEmail author
  • Blair Jarvis
Adis New Drug Profile

Abstract

  • ▴ Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system.

  • ▴ In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20 mg/day was at least as effective as atenolol 50 to 100 mg/day in reducing diastolic blood pressure (DBP). At dosages of 5 to 20 mg/day, olmesartan medoxomil was more effective than captopril 12.5 to 50mg twice daily at lowering seated DBP in patients with mild to moderate hypertension in a dose titration study.

  • ▴ Reductions in seated DBP were greater with olmesartan medoxomil 10 to 20 mg/day than losartan 50 to 100 mg/day. Olmesartan medoxomil at 20 mg/day was more effective in lowering seated DBP than losartan 50 mg/day, valsartan 80 mg/day or irbesartan 150 mg/day, and was more efficacious than losartan 50 mg/day or valsartan 80 mg/day at reducing 24-hour ambulatory systolic blood pressure.

  • ▴ Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide).

  • ▴ Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo. With olmesartan medoxomil, the frequency of dizziness was higher than with placebo but similar to that occurring with losartan, valsartan and irbesartan.

Keywords

Diastolic Blood Pressure Losartan Valsartan Irbesartan Olmesartan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bloom BS. Daily regimen and compliance with treatment. Br Med J 2001 Sep 22; 323: 647CrossRefGoogle Scholar
  2. 2.
    Benson S, Vance-Bryan K, Raddatz J. Time to patient discontinuation of antihypertensive drugs in different classes. American Journal of Health-System Pharmacists 2000 Jan 1; 57(1): 51–4Google Scholar
  3. 3.
    Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–8PubMedCrossRefGoogle Scholar
  4. 4.
    Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001 Jun; 19 Suppl. 1: 3–14Google Scholar
  5. 5.
    Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade on nitric oxide synthesis in rats. Circulation 2000 Jan; 101: 305–10PubMedCrossRefGoogle Scholar
  6. 6.
    Takemoto M, Egashira K, Tomita H, et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997 Dec; 30: 1621–7PubMedCrossRefGoogle Scholar
  7. 7.
    Tomita H, Egashira K, Ohara Y, et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998 Aug; 32: 273–9PubMedCrossRefGoogle Scholar
  8. 8.
    Koike H. New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr 19; 87(8A): 33–6CrossRefGoogle Scholar
  9. 9.
    Mizuno M, Sada T, Ikeda M, et al. Effects of CS-866 on hypertensive nephropathy in SHR and DOCA rats [abstract no. P-70]. Jpn J Pharmacol 1997; 73 Suppl. 1: 135Google Scholar
  10. 10.
    Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 2002 May; 16 Suppl 2: S7–S12PubMedCrossRefGoogle Scholar
  11. 11.
    Laeis P, Nussberger J, Püchler K, et al. Dose-response relationship of the oral angiotensin II-antagonist CS-866 in healthy male subjects [abstract no. P1.168]. J Hypertens 1999 May; 17 Suppl. 3: 67Google Scholar
  12. 12.
    Püchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997; 15 (12 Part 2): 1809–12PubMedCrossRefGoogle Scholar
  13. 13.
    Kawaratani T, Laeis P, Püchler K, et al. The effect of an antacid (aluminum magnesium hydroxide) on the pharmacokinetics and safety of the oral antiotensin II-antagonist CS-866 in healthy, male subjects [abstract no. 145]. J Hypertens 1999 May; 17 Suppl. 3: S243Google Scholar
  14. 14.
    Kawaratani T., Püchler K., Laeis P., et al. Steady state pharmacokinetics of CS-866, a novel angiotensin II-receptor antagonist in elderly and young hypertensive patients [abstract no. P.9]. J Hum Hypertens 1999 May; 13: 3Google Scholar
  15. 15.
    Laeis P, Püchler K, Witte P, et al. Pharmacokinetics of the new oral angiotensin II-antagonist CS-866 [abstract no. 460]. Eur J Clin Pharmacol 1997; 52 Suppl.: 148Google Scholar
  16. 16.
    Kawaratani T, Püchler K, Laeis P, et al. Pharmacokinetics of RNH-6270, the active metabolite of the oral angiotensin II-antagonist CS-866, in healthy, male subjects [abstract no. 146]. J Hypertens 1999 May; 17 Suppl. 3: 244Google Scholar
  17. 17.
    Laeis P, Püchler K, Witte PU, et al. The pharmacokinetic profile of CS-866 [abstract no. 169]. J Hypertens 1997; 15 Suppl. 4: 158Google Scholar
  18. 18.
    Püchler K, Nussberger J, Witte P U, et al. Pharmacokinetic, safety and tolerability studies of the oral angiotensin II-antagonist olmesartan medoxomil in young, elderly and verly elderly patients with hypertension [abstract no. P2.180]. J Hypertens 2001 Jun; 19 Suppl. 2: 154Google Scholar
  19. 19.
    Laeis P, Püchler K, von Bergmann K. A comparative pharmacokinetic, safety and tolerability trial of the oral angiotensin II-antagonist olmesartan medoxomil in subjects with varying degrees of renal impairment and in health volunteers [abstract no. P2.147]. J Hypertens 2001 Jun; 19 Suppl. 2: 145Google Scholar
  20. 20.
    Püchler K, Laeis P, Kawaratani T, et al. The effect of the combination of the oral angiotensin II-antagonist CS-866 and warfarin on pharmacodynamics, pharmacokinetics and safety in healthy, male subjects [abstract no. 271]. J Hypertens 1999 May; 17 Suppl. 3: 275Google Scholar
  21. 21.
    Laeis P, Püchler K, Kirch W The effect of the oral angiotensin II-antagonist olmesartan medoxomil on the safety, tolerability and pharmacokinetics of digoxin in healthy, male subjects [abstractno. P2.179]. J Hypertens 2001 Jun; 19 Suppl. 2: 154Google Scholar
  22. 22.
    Püchler K, Laeis P, Gunther A, et al. Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension [abstract no. P11]. J Hum Hypertens 1999 May; 13 Suppl. 3: 4Google Scholar
  23. 23.
    Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41(5): 515–27PubMedCrossRefGoogle Scholar
  24. 24.
    Masonson HN, Punzi HA, Neutel JM, et al. CS-866 (angiotensin-II receptor antagonist): a double-blind study using ambulatory blood pressure monitoring in hypertensive patients[abstract no. D035]. Am J Hypertens 1998; 11 (4 Pt. 2): 77CrossRefGoogle Scholar
  25. 25.
    Püchler K, Laeis P, Witte P U, et al. Antihypertensive efficacy of CS-866, a novel angiotensin-II antagonist [abstract no. 293]. J Hypertens 1997; 15 Suppl. 4: 185Google Scholar
  26. 26.
    Van Mieghem W A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus atenolol in patients with mild to moderate essential hypertension [abstract no. P2.174]. J Hypertens 2001 Jun; 19 Suppl. 2: 152Google Scholar
  27. 27.
    Püchler K, Laeis P, Stumpe K O. A comparison of the efficacy and saftey of the oral angiotensin II-antagonist olmesartan medoxomil with those of atenolol in patients with moderate to severe hypertension under continuous treatment with hydrochlorothiazide [abstract no. P2.175]. J Hypertens 2001 Jun; 19 Suppl. 2: 153Google Scholar
  28. 28.
    Williams P A. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus captopril in patients with mild to moderate essential hypertension [abstract no. 207]. J Hypertens 2001 Jun; 19 Suppl. 2: 300Google Scholar
  29. 29.
    Ball K. A multi-centre, double-blind, efficacy, tolerability and safety study of the oral angiotensin II-antagonist olmesartan medoxomil versus losartan in patients with mild to moderate essential hypertension [abstract no. P2.176]. J Hypertens 2001 Jun; 19 Suppl. 2: 153Google Scholar
  30. 30.
    Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001 Sep 31; 3(5): 283–91CrossRefGoogle Scholar
  31. 31.
    Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001 Jun; 19 Suppl. 1: 49–56Google Scholar
  32. 32.
    Püchler K, Laeis P, Stumpe K O. Dose related differences in blood pressure response are not related to adverse event incidence [abstractno. P1.191]. J Hypertens 2001 Jun; 19 Suppl. 2: 70Google Scholar
  33. 33.
    Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001 Apr 19; 87(8A): 37–43CrossRefGoogle Scholar
  34. 34.
    Benicar™tablets (olmesartan medoxomil) [online]. Available from URL: http://www.fda.gov/ [Accessed 2002 Apr 30]

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations